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Abstract 
Cytochrome P-450 BM3 from Bacillus megaterium catalyses NADPH oxidation in the absence of added substrate. This activity is 
also associated with the independently expressed flavin-containing reductase domain of the protein. The rates of these activities are more 
than two orders of magnitude lower than those in the presence of fatty acid P-450 substrates or artificial electron acceptors. Electrons 
derived from NADPH in this fashion are transferred onto oxygen, generating superoxide (O~) anions. The formation of these active 
oxygen species is detectable by luminometry and the chemiluminescence can be inhibited through the addition of superoxide dismutase 
(but not catalase). This activity is reminiscent of the microbicidal NADPH oxidase activity associated with neutrophils and other 
leukocyte blood cell types. Diphenyliodonium, a potent inhibitor of the neutrophil NADPH oxidase, effectively inhibits fatty acid 
hydroxylase and electron transferase activities catalysed by P-450 BM3 and its reductase domain. CD studies on the native and 
NADPH-reduced P-450 BM3 and BM3 reductase indicate that no secondary structural alteration is caused by pre-incubation with the 
reductant. Therefore, the previously recognised reversible time-dependent i activation of P-450 BM3 by NADPH may be attributed to 
the NADPH oxidase activity associated with the reductase domain of the enzyme. 
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I. Introduction 
The cytochromes P-450 are a ubiquitous uperfamily of 
enzymes which catalyse monooxygenation f a wide vari- 
ety of organic compounds [1]. In mammals, these reactions 
may be necessary for the interconversions of endogenous 
metabolites, or may serve to increase the solubility of 
drugs and xenobiotics to facilitate their excretion. In mi- 
crobes, activity of P-450s may be required for physio- 
logical biotransformations or to allow utilisation of un- 
usual organic compounds as energy sources [2]. A number 
of P-450s from plants have been identified, with important 
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functions in the biosynthesis of cuticles and plant hor- 
mones and detoxification of herbicides [3]. A large litera- 
ture has also accumulated on the subject of the P-450s 
from fungi and yeasts [4]. 
Cytochrome P-450 BM3 is isolated from the Gram 
positive bacterium Bacillus megaterium and catalyses hy- 
droxylation of long chain fatty acids, alcohols and amides 
as well as the epoxidation/hydroxylation of unsaturated 
fatty acids [5,6]. P-450 BM3 is unique among the P-450s 
in that it is 'catalytically self sufficient'. While activity of 
other P-450 systems relies on either one or two additional 
protein electron transferring components, P-450 BM3 re- 
quires only fatty acid substrate and NADPH for full activ- 
ity [7]. The enzyme is comprised of an FAD-and FMN- 
containing NADPH-cytochrome P-450 reductase 'domain' 
fused at the C-terminal of the P-450 domain in a single 
polypeptide chain [8]. 
Like all bacterial P-450s, P-450 BM3 is a soluble 
enzyme. However, other bacterial P-450 systems are com- 
prised of three components; the P-450, an iron-sulfur 
redoxin and a flavoprotein redoxin reductase. The best 
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example of these 'class I' P-450s [9] is the P-450cam 
system from Pseudomonas putida, for which a high-reso- 
lution atomic structure has been determined [10]. P- 
450cam has been used as a structural model for the entire 
P-450 superfamily. 'Class II' systems are two-component 
(NADPH-cytochrome P-450 reductase and P-450) and 
contain members involved in drug and xenobiotic 
metabolism [1,9]. P-450 BM3 is an unusual example of a 
class II system, in which the reductase is linked to the 
P-450. The haem-containing domain of P-450 BM3 has 
been crystallised [9,11,12] and the first atomic structure of 
a class II P-450 was published recently [13]. Comparison 
of the structures of P-450cam and P-450 BM3 reveal that, 
while the overall fold (resembling a triangular prism) and 
secondary structure contents are similar, the helical ar- 
rangements in the haem domain of P-450 BM3 differ 
significantly from those in P-450cam and there are four 
major peptide insertions (of between 7 and 17 amino 
acids) within P-450 BM3 haem domain with respect o 
P-450cam [13]. However, P-450 BM3 may be a more 
accurate model for the mammalian class II systems, since 
it is much closer in size to the majority of them than is 
P-450cam, has much higher primary structure similarity to 
eukaryotic lass IV P-450 enzymes than to any other 
bacterial P-450 arid might also be expected to retain 
structural motifs required for interaction with the distinct 
redox partner [13-15]. 
The reductase domain of P-450 BM3 is one of a small, 
but evolutionarily strongly conserved, family of flavo- 
protein reductases which bind NADPH and contain both 
FAD and FMN prosthetic groups [16]. This family also 
contains eukaryotic P-450 reductase, the flavoprotein 
components of nitric oxide synthase from the rat [17] and 
sulfite reductase from Salmonella ~phimurium [18,19]. 
These flavoproteins appear to have evolved from the fu- 
sion of genes encoding two distinct classes of flavoprotein, 
a ferredoxin-NADP + reductase (FNR)-like transhydro- 
genase and a flavodoxin-like electron transferase [16]. The 
transhydrogenase (FNR) subdomain of P-450 BM3 ex- 
hibits significant similarity to other NADH and NADPH 
reductases from the FNR 'family' of reductases, particu- 
larly in regions involved in binding FAD and dinucleotide 
cofactors [20,21]. These include the ¢3-subunit of flavocy- 
tochrome b-245, a component of the microbicidal NADPH 
oxidase of phagocytes [21 ]. 
The NADPH oxidase is an electron transport system 
found in neutrophils and other phagocytic ells [22], the 
components of which have also been located in T and B 
lymphocytes [23]. Its function is to reduce oxygen with 
electrons from NADPH, producing superoxide radicals and 
resulting in the effective killing of pathogens ingested by 
the phagocytes. It appears that a membrane-bound flavocy- 
tochrome b contains the full electron transporting appara- 
tus of the NADPH oxidase [24], but that cytosolic factors 
are involved in its regulation [21]. The flavocytochrome is 
composed of a 21 kDa c~-subunit, which is probably the 
site of attachment of the haem moiety, and a /3-subunit 
with an apparent molecular mass of approx. 92 kDa [21]. 
The /3-subunit s a heavily glycosylated flavoprotein dehy- 
drogenase [24], which has previously been reported to 
catalyse the production of superoxide independently of the 
c~-subunit under non-physiological conditions [25]. 
In this report we investigate the ability of flavocy- 
tochrome P-450 BM3 and its isolated domains to act as 
NADPH oxidases, utilising certain experimental methods 
previously applied in studies of the phagocyte enzyme. We 
also investigate the susceptibility of activities of these 
proteins to an inhibitor (IDP) of the phagocyte nzyme, in 
order to identify the major oxidase site. Finally, we use 
enzymic and spectroscopic (CD) methods to investigate a 
previous theory that pre-incubation of P-450 BM3 with 
NADPH induces a time-dependent, reversible inactivation, 
and that this inactivation may involve a conformational 
change in the enzyme [7]. 
2. Materials and methods 
2.1. E. coli strains, plasmid and bacteriophage vectors 
E. coli strains TG1 (supE, hsdA5, thi, A(lac-proAB), 
F' [traD36, proAB +, lacI q, lacZAMl5]) [26] and XL-I 
Blue (supE44, hsdR17, recAl, gyrA46, thi, relA1, lac, 
F' [proAB +, lacI q, lacZAM15, Tnl0(tetr)]) [27] were 
used for plasmid propagation and the overexpression f the 
gene encoding cytochrome P-450 BM3 (cypl02) and the 
PCR-generated subgenes encoding its constituent reductase 
and haem 'domains'. Plasmid construct pJM23 was used 
for expression of P-450 BM3 in E. coli. The plasmid 
consists of a 5kb segment of B. megaterium chromosomal 
DNA (containing the q,;pl02 gene) cloned as a Xbal- 
EcoRI restriction fragment into vector pUC119 [28] and 
expression is from the Bacillus promoter [12]. Plasmid 
construct pJM27 was used for the expression of the flavo- 
protein reductase domain of P-450 BM3 (residues 473 to 
end) and consists of an approx. 1.8 kb PCR fragment of 
cypl02 cut with BamHI (to generate cohesive nds from 
restriction enzyme sites engineered at 5' ends of PCR 
primers) and cloned into vector ptac85 [29] under an 
inducible tac promoter [12]. Plasmid construct pJM20 was 
used for the expression of the haem-containing domain of 
P-450 BM3 (residues 1 to 472) and consists of an approx. 
1.5 kb PCR fragment of cypl02 cut with EcoRI and 
BamHI (to generate cohesive ends as with pJM27) and 
cloned into vector pUC118 [28] under the lac promoter 
[12]. 
2.2. Molecular biology techniques 
DNA manipulations, bacterial transformations and other 
molecular techniques were performed by standard methods 
[30]. 
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2.3. Expression and purification of  intact cytochrome P-450 
BM3 and its constituent domains 
E. coli transformants carrying plasmids encoding wild- 
type P-450 BM3 and its constituent flavoprotein reductase 
domain were grown overnight o high cell density in 
Terrific Broth plus antibiotic (ampicillin) [31]. IPTG in- 
ducer (final concentration 25 /zg/ml) was added to facili- 
tate expression from plasmids pJM27 (encoding the reduc- 
tase domain) and pJM20 (encoding the haem-containing 
domain). Wild-type P-450 BM3 was expressed from plas- 
mid pJM23 under the control of its own promoter and 
without induction, as previously described [12]. A signifi- 
cant increase in the level of expression of intact P-450 
BM3 (approx. 3-fold) was seen to occur if the culture of 
pJM23 transformants was grown to stationary phase, as 
has been previously reported [32]. 
30-35 g of wet cell pellets were the starting points for 
purification of the polypeptides. Following cell rupture by 
French pressure, polypeptides were purified to homogene- 
ity by successive steps of ammonium sulfate precipitation, 
ion exchange chromatography on DEAE-Sephacel and ei- 
ther affinity chromatography on 2',5'-ADP-Sepharose (in
the case of intact P-450 BM3 and its reductase domain) or 
by affinity for Bio-Gel HTP (DNA grade) hydroxyapatite 
(in the case of the haem domain) as previously described 
[ 12]. Purification of the polypeptides by gel filtration using 
Sephacryl S-300 HR was used as a final purification step, 
if required. 
Circular dichroism spectra were recorded at 20°C on a 
JASCO J-600 spectropolarimeter. NADPH 'blanks' were 
also recorded in order to correct for its contribution in 
'Enzyme plus NADPH' spectra. Molar ellipticity values 
were calculated using a value of 112 (calculated from 
amino acid sequences) for the mean residue weights. Anal- 
ysis of the secondary structure content was undertaken by 
using the CONTIN procedure [37]. 
2.5. Luminometr3' 
Luminometry was performed on an LKB Wallac 1250 
display luminometer linked to a Datel Systems DPP Q7 
printer. Assay systems contained 100 /zl of enhancer 
(either 1 mM lucigenin [bis-N-methylacridinium nitrate] or 
1-10 mM luminol [5-amino-2,3-dihydro-l,4-phthalazine- 
dione]), 15/zl of 20 mM NADPH, 1-10/zl of enzyme and 
assay buffer (20 mM Mops [pH 7.4] + 100mM KCI) to 1 
ml. Deionised, double distilled water was used for all 
solutions utilised in luminometry experiments. 
2.6. Materials 
Molecular biology reagents were purchased from 
Boehringer or United States Biochemicals. Radiochemicals 
were obtained from Amersham International. DEAE-Seph- 
acel was purchased from Pharmacia-LKB. Diphenyliodo- 
nium chloride (IDP) was from Aldrich. All other reagents 
and enzymes were from Sigma. 
2.4. Spectroscopy, protein and enzyme assays 
All UV-visible spectroscopy was performed on a Shi- 
madzu 2100 spectrophotometer (Shimadzu, Kyoto, Japan). 
Protein concentrations were determined using the method 
of Bradford [33] and by the BCA technique [34] with BSA 
as standard. Cytochrome P-450 concentrations were esti- 
mated by the method of Omura and Sato [35] using c = 91 
mM-~ cm-~ at 450 nm for the reduced plus CO adduct. 
Cytochrome c reduction was determined using ~ = 21 
mM ~ cm ] at 550 nm, as previously described, except 
that the buffer system used was 20 mM Mops (pH 7.4) 
containing 100 mM KC1 [12]. NADPH-dependent fatty 
acid hydroxylation was measured at 30°C in the same 
buffer containing 0.5 mM sodium laurate and 0.2 mM 
NADPH, ~ = 6.2 mM ] cm-1 at 340 nm. Catalase activ- 
ity was measured at 30°C by monitoring the increase in 
absorbance at 240 nm in the same buffer system contain- 
ing 10.5 mM hydrogen peroxide and 3 units (/zmol/min 
under the conditions pecified in the Sigma catalogue) of 
catalase. Xanthine oxidase activity was measured at 30°C 
as the superoxide-dependent rateof cytochrome c reduc- 
tion in the same buffer system, as described by Kuthan et 
al. [36]. Deionised, double distilled water was used in all 
solutions. Rates shown are the means of at least three 
separate determinations, differing by less than 10%. 
3. Results 
3.1. Substrate independent NADPH oxidation by P-450 
BM3 and its reductase domain 
P-450 BM3 catalyses rapid substrate-dependent NADPH 
oxidation. Rates as high as 77 s-L (4620 mol/min per 
mol) have been reported for the hydroxy|ation of saturated 
fatty acids [7]. It has been observed that NADPH oxidation 
by P-450 BM3 also occurs in the absence of a substrate or 
added electron acceptor, albeit at a much lower rate. 
Substrate-independent oxidation of NADH occurs at an 
extremely slow rate ( < 0.1 nmol/min per nmoi enzyme). 
The NADPH oxidase property of P-450 BM3 is retained 
by its independently expressed reductase domain, but not 
by the haemoprotein domain. The rates are very similar for 
P-450 BM3 and its flavin domain (Table 1). The rates in 
the absence of substrate are approx. 103-fold lower than 
those in the presence of substrate. Extensive dialysis was 
performed to separate any possible substrate from the 
purified enzymes prior to initiation of the assays. The fact 
that haem iron is essentially all low spin in purified intact 
P-450 BM3 confirms the absence of fatty acid substrate 
[12]. Since NADPH oxidase activity was associated with 
the flavoprotein reductase domain (but not the haem-con- 
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Table 1 
NADPH oxidation rates by P-450 BM3 and its constituent domains in the 
presence and absence of substrates and IDP 
Enzyme NADPH oxidation rates in presence/absence 
of substrates (nmol/min per nmol enzyme) 
substrate absent cytochrome c lauric acid 
BM3 2.15 (2.05) 3378 1191 
BM3 + IDP 36.4 (0.85) 122 15.6 
R dora. 2.1 (2.0) 2964 < 0.1 
R dom.+IDP 39.2(0.7) 49 <0.1 
Pdom. <0.I <0.1 <0.1 
P dom.+IDP <0.1 <0.1 <0.1 
For intact P-450 BM3 (BM3) and its reductase (R dom.) and P-450 (P 
dora.) domains, 'substrate absent' NADPH oxidation was measured by 
absorbance d crease at 340 nm (6.2 mM -t cm- I) at 30°C in a system 
containing enzyme, NADPH (0.2 raM) and assay buffer (20 mM Mops 
(pH 7.4)+ 100 mM KCI) to 1 ml. 'Substrate present' rates were measured 
in the same buffers following addition of 25 tzM cytochrome c (2 lmM- i 
cm-I at 550nm) or0.5 mM sodiumlaurate (6.2 mM i cm t at 340 
nm). Final enzyme concentrations of approx. 40 nM ('substrate present') 
and 2 /zM ('substrate absent') were used in the assays. The inhibitor IDP 
was added to a final concentration f 500 IzM and the 'substrate absent' 
rates after 10 rain are shown in parentheses. 
taining P-450 domain), it appeared that in both the reduc- 
tase domain and intact P-450 BM3 electrons from NADPH 
were passing onto the reductase domain to reduce the 
flavins (FAD and FMN; joint capacity of four reducing 
equivalents). However, the fact that (in systems containing 
2 /~M enzyme and 0.2 mM NADPH) slow substrate-inde- 
pendent NADPH oxidation was linear over periods of 
greater than 30 min indicated that the process was not 
completed by reduction of FAD and FMN. For both P-450 
BM3 and its flavin domain, the enzymes oxidised more 
than 10-fold their molar equivalent of NADPH over this 
period. No oxidation of NADPH occurred in the absence 
of added enzyme and none was catalysed by the isolated 
haem domain of P-450 BM3. Using similar quantities of 
P-450 BM3 and cofactor, NADPH oxidation was seen to 
continue for more than 1 h (data not shown). It is evident 
that electrons must depart from flavin(s) of P-450 BM3 
and BM3 reductase to an acceptor in solution. Oxygen is 
likely to be this acceptor and its reduction could lead to the 
generation of superoxide (O~-) anions and/or  hydrogen 
peroxide (H202). In support of this conclusion, purging of 
buffer solutions with nitrogen for 2 min prior to initiation 
of the assays resulted in decreases of more than 65% in the 
rates of P-450 BM3-and BM3 reductase-catalysed sub- 
strate-independent NADPH oxidation, whereas the rate of 
cytochrome c reduction remained unchanged (data not 
shown). 
3,2. Luminometric detection of  actit, e oxygen species 
Assays were performed to detect products of oxygen 
activation using luminometry. In assay systems containing 
either intact P-450 BM3 or its reductase (flavin) domain 
and NADPH, the production of active oxygen species was 
detected by the luminescence of lucigenin. No such prod- 
ucts were detected in experiments using the isolated P-450 
(haem) domain (Fig. 1), indicating, again, that the flavo- 
protein reductase domain of P-450 BM3 provides the 
route by which electrons depart and that these electrons 
may be transferred irectly from this domain onto 0 2 . The 
luminescence detected using luminol was found to be 
lower than that using lucigenin by a factor of approx. 20 
(Fig. 2). There was no detectable stimulation of NADPH 
oxidation by lucigenin under the conditions employed in 
the luminometry assays. Therefore, it is not the case that 
direct reduction of lucigenin is the reason for the differ- 
ence in luminescence seen between systems containing 
lucigenin and luminol. Since lucigenin luminescence can 
be decreased approx. 20-fold by the addition of superoxide 
dismutase (SOD), but not by catalase, it is clear that 
superoxide production through the reductase domain of 
P-450 BM3 is the main cause of lucigenin luminescence. 
Fig. 3 demonstrates the effect of addition of 250 units of 
SOD on P-450 BM3-mediated lucigenin luminescence. 
Addition of higher quantities of SOD further reduced the 
chemiluminescence. It is possible that residual lumines- 
cence (< 3% of original) may result from direct reduction 
of lucigenin. The lower level of luminescence detected 
using luminol can also be decreased to a similar extent 
using SOD (data not shown), indicating that 0 2 ions are 
mainly responsible for luminescence detected using both 
compounds. Assays of catalase (hydrogen peroxide break- 
down) and SOD (inhibition of cytochrome c reduction in a 
xanthine/xanthine oxidase system) indicated that both en- 
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Fig. 1. Lucigenin chemiluminescence produced by P-450 BM3 and BM3 
reductase catalysed NADPH oxidation. Luminescence of lucigenin (final 
concentration 100/xM) was monitored at30°C as described inthe Materi- 
als and Methods ection. Mixtures contained 1.0 txM enzyme and 
reactions were initiated by the addition of 0.3 mM NADPH. Symbols: 
([]) intact P-450 BM3, (• )  P-450 domain, (• )  reductase domain. 
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Fig. 2. Comparison of lucigenin and luminol chemiluminescence pro- 
duced uring NADPH oxidation, The relative intensity of luminescence 
produced by P-450 BM3 catalysed NADPH oxidation was measured in 
systems containing either 100 ~M lucigenin (0)or  100 /xM luminol 
(D). Assays were performed at30°C as described in the Materials and 
Methods ection, using 2 /xM P-450 BM3. A similar esult was obtained 
when the reductase domain of P-450 BM3 was used for the same 
experiments (not shown). 
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Fig. 4. Effect of diphenyl iodonium on P-450 BM3 catalysed lucigenin 
chemiluminescence. Progressive inhibition of the burst of P-450 BM3 (2 
/xM) catalysed luminescence was achieved by the addition of increasing 
concentrations of diphenyliodonium chloride (IDP). Symbols: (D) no 
IDP added, (•)  0.25 mM IDP, (• )  1 mM IDP and (~) 2.5 mM IDP. 
Assays were performed at 30°C as described in the Materials and 
Methods ection. 
zymes retained > 90% of their activities in the presence of 
up to 100 /xM luminol and lucigenin (data not shown). 
Mannitol (an inhibitor of hydroxyl radical formation) and 
various chelators of divalent iron (EDTA, 2,2'-dipyridyl, 
ethylenediamine di(o-hydroxyphenylacetic acid)) were 
without significant effect on the luminescence at concen- 
trations up to 0.5 raM, again indicating that reductase- 
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Fig. 3. Effect of superoxide ismutase on P-450 BM3 catalysed lucigenin 
chemiluminescence. Th  pronounced ffect of addition of 250 units of 
SOD on the luminescence caused by P-450 BM3 (0.75 /~M) mediated 
NADPH oxidation is shown (Symbols: ([]) no SOD added, (0) 250 
units SOD added). Assays were performed at30°C as described in the 
Materials and Methods ection. 
mediated generation of superoxide ions was the main basis 
of the luminescence d tected (data not shown). 
Experiments were performed to monitor NADPH oxida- 
tion during the catalytic processes of lauric acid hydro×yl- 
ation (intact P-450 BM3) and cytochrome c reduction 
(P-450 BM3 and BM3 reductase) in the presence of 100 
/zM lucigenin. In all cases, initial rapid rates were quickly 
seen to slow considerably and activity came to a stop 
within approx. 45 s (data not shown). It would seem clear 
that the chemiluminescent ('activated') form of the com- 
pound causes inhibition of the activities of P-450 BM3 
and its reductase. This would explain the rather short span 
of the chemiluminescent bursts seen in the experiments 
reported here. 
A parallel experiment was performed in which slow, 
continuous consumption of oxygen was recorded using an 
oxygen electrode containing only assay buffer, NADPH 
(0.2 raM) and either P-450 BM3 or its reductase domain at 
a final concentration of 2 ~M. The initial rate of oxygen 
consumption measured in both cases was 2 nmol oxygen 
consumed/min /nmol  enzyme -very similar to the 
NADPH oxidation rates for these polypeptides (Table 1). 
No oxygen consumption was observed in the absence of 
enzyme, or when the haem domain of P-450 BM3 was 
used. 
3.3. Inhibition of NADPH oxidase actiL,i~, by diphenyl- 
iodonium chloride 
Addition of sub-millimolar concentrations of IDP effec- 
tively inhibited P-450 BM3 catalysed sodium laurate hy- 
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droxylation and cytochrome c reduction, and also cy- 
tochrome c reduction catalysed by BM3 reductase (Table 
1). The addition of IDP was also found to inhibit lucigenin 
chemiluminescence caused by the NADPH oxidase activ- 
ity of P-450 BM3. Fig. 4 shows the progressive inhibitory 
effect of increasing concentration of IDP on the chemilu- 
minescent burst caused by P-450 BM3-catalysed NADPH 
oxidation. Similar results were obtained using the BM3 
reductase. This indicates that this domain carries the IDP- 
inhibitable site of P-450 BM3, which is likely to be one or 
both of the flavins. IDP does not appear to interact with 
the haem of P-450 BM3 in the presence or absence of 
NADPH, as evidenced by the lack of alteration in the 
haem region of the visible spectrum of P-450 BM3 on 
addition of 1 mM IDP (data not shown). In any case, 
interaction with P-450 haem would not be expected to 
inhibit the substrate independent NADPH oxidase activity 
associated with the flavoprotein domain of P-450 BM3. 
IDP did not affect luminescence of lugigenin caused by 
superoxide generated in a xanthine/xanthine oxidase sys- 
tem (data not shown). 
Experiments in which the effect of IDP on substrate-in- 
dependent NADPH oxidation were monitored revealed that 
the initial rate of P-450 BM3 and BM3 reductase mediated 
oxidation of NADPH is significantly increased in the 
presence of low concentrations of IDP (Table 1). This 
indicates that IDP is reduced by BM3 and its reductase. 
The IDP radical formed may then react back with flavin to 
inactivate the enzymes -as previously postulated for the 
mechanism of inhibition of the neutrophil NADPH oxidase 
by iodonium compounds [38], and as recently demon- 
strated for the inhibition of rat P-450 reductase [39]. Thus, 
while NADPH oxidation may initially be stimulated in the 
presence of IDP, superoxide anion production would be 
inhibited. This inhibition may occur initially due to compe- 
tition between IDP and oxygen for electrons from the 
reduced flavin(s), but will later be due to inactivation of 
these redox centres by covalent linkage of IDP -a  'suicide 
substrate' for the BM3 reductase. Table 1 shows that while 
BM3 reductase-catalysed NADPH oxidation is relatively 
constant over a period of 10 min, the rate in the presence 
of 500 /zM IDP decreases dramatically as the inhibitory 
IDP radical product is formed. As expected, 30 rain pre-in- 
cubations of P-450 BM3 and its reductase with a 10-fold 
o Io[ a 
0.06C 
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O~dl~l .  
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O. 04( 
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O. 02C 
5 L 
O. 0 0 4 1 ~  J O. 003 L_ . . . . . . . . . . . . . . . . . . . . . . .  : . . . . .  , . . . . . . . . .  "I 
412.1 450.0 500.0 550.0 600.0 642.4 400.0 450.0 500.0 550.0 596.6 
Wavelength (rim) Wavelength (nm) 
Fig. 5. Effect of diphenyliodonium onreoxidation of flavins in P-450 BM3 reductase domain. A solution of 6 /zM BM3 reductase in assay buffer (20 mM 
Mops (pH 7.4) + 100 mM KC1) was reduced with 500 /iM NADPH at 20°C. Visible spectra were recorded in the region of the major flavin absorbance 
band (approx. 460 nm) for the oxidised and reduced forms, and further spectra were taken at the time intervals indicated in minutes (a). (b) shows the 
inhibitory effect of addition of 1 mM IDP (at time zero) on the reoxidation of the flavins of BM3 reductase under the same conditions. 
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molar excess of IDP did not result in inactivation of the 
enzymes. Activity was retained when (200-fold) diluted 
samples of these mixtures were used in cytochrome c
reduction assays. However, inclusion of a similar excess of 
NADPH in the pre-incubation buffer resulted in the loss of 
> 85% cytochrome c reducing ability, indicating that en- 
zyme (and hence IDP) reduction is a prerequisite for 
inhibition (data not shown). As seen by visible spec- 
troscopy, flavins of BM3 reductase reoxidise over time 
following the addition of an 80-fold molar excess of 
NADPH to the enzyme (Fig. 5a). Under the conditions 
used, reoxidation is complete after approx. 150 min -when 
the visible spectrum becomes virtually identical to the 
original oxidised spectrum in the region scanned. This 
reoxidation does not occur in the presence of 1 mM IDP 
(Fig. 5b) -providing further evidence for the flavins as the 
site of inhibition by IDP. Recently, we have shown that 
flavins can be dissociated from P-450 BM3 and its reduc- 
tase by incubation with the denaturant guanidinium chlo- 
ride at concentrations which do not irreversibly denature 
the enzymes (less than approx. 1.5 M). It is possible to 
regenerate more than 50% of the enzyme activity lost by 
NADPH/IDP treatment through incubation in approx. 0.5 
M GdnHCI (to dissociate the modified flavins) and dilu- 
tion to assay buffer containing 10-fold molar excess free 
FAD and FMN (Munro et al., unpublished ata). 
3.4. Effect of NADPH on the CD spectra of P-450 BM3 
and its reductase domain 
In view of the previous report [7] suggesting that time- 
dependent inactivation of P-450 BM3 on incubation with 
NADPH was associated with a conformational change in 
the protein, we monitored the effect of NADPH on the 
P-450 BM3 and BM3 reductase using CD. Fig. 6 shows 
the effect of enzyme incubation with NADPH on the far 
UV-CD spectra of P-450 BM3 (Fig. 6a) and BM3 reduc- 
tase domain (Fig. 6b). Only very minor alterations in the 
spectra are observed following 90 rain incubations with 
NADPH, indicating that the secondary structure of the 
enzymes is not significantly perturbed by the NADPH. 
Fig. 7 shows the effect of the same incubations on the 
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Fig. 6. Effect of NADPH on the far-UV-CD spectra of P-450 BM3 and BM3 reductase domain. Solutions of (a) P-450 BM3 and (b) BM3 reductase 
domain were at concentrations of 0.46 mg/ml.  Each solution was mixed with NADPH (0.2 raM) and incubated at room temperature for approx. 90 min. 
CD spectra were collected before and after these incubations as described in the Materials and Methods section. The small spectral contributions due to 
NADPH were subtracted using appropriate blanks. 
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Fig. 7. Effect of NADPH on the visible-CD spectra of P-450 BM3 and BM3 reductase domain. Solutions of (a) P-450 BM3 and (b) BM3 reductase 
domain were at concentrations of 1.38 mg/ml. Each solution was mixed with NADPH (0.2 mM) and incubated at room temperature for approx. 60 min. 
CD spectra were collected before and after these incubations as described in the Materials and Methods section. The small spectral contributions due to 
NADPH were subtracted using appropriate blanks. 
near UV-visible CD spectra of P-450 BM3 (Fig. 7a) and 
BM3 reductase (Fig. 7b). Clear differences in this region 
are seen to result from incubation with NADPH, and, 
although the signals from the BM3 reductase domain are 
weak, these can be largely ascribed to the alteration in 
signals from the reduced FAD and FMN chromophores. 
4. Discussion 
The results presented in this report clearly demonstrate 
the ability of cytochrome P-450 BM3 and its reductase 
domain to oxidise NADPH in the absence of fatty acid 
substrates or artificial electron acceptors, such as cy- 
tochrome c. Chemiluminescence experiments indicate that 
the electrons derived from NADPH oxidation are trans- 
ferred onto oxygen to generate superoxide anions. Addi- 
tion of superoxide dismutase inhibits this luminescence. 
Chemiluminescence has been widely used in the study of 
microbicidal NADPH oxidase of leukocytes, e.g., [23,40]. 
It has not been extensively used in the study of P-450 
systems, but here we show that it provides a useful tech- 
nique for detection of 02 and represents a convenient 
alternative to spectroscopic techniques (such as EPR and 
spin-trapping) [41] or the measurement of NADPH-depen- 
dent lipid peroxidation [42] previously used for the detec- 
tion of O~- produced by mammalian P-450 reductase. 
Attempts to measure O~- production by following the 
superoxide dismutase-sensitive rate of cytochrome c re- 
duction are made extremely difficult due to the high 
inherent cytochrome c reductase activity of P-450 reduc- 
tase. 
The reduction of 02 to O~ is the function of the 
microbicidal NADPH oxidase of leukocytes and other 
white blood cell forms. The haemoprotein component of 
this complex flavocytochrome [24] appears vital for oxy- 
gen activation [43,20]. The low-potential type b haem in 
the NADPH oxidase (cytochrome b-245) is six coordinate, 
with two strong axial amino acid ligands to the haem iron 
[22]. This cytochrome is therefore dissimilar from the 
cytochromes P-450, which have a single axial haem ligand 
(a cysteine residue) and the second axial position vacant 
for the iigation and activation of oxygen during catalysis 
[44]. In the NADPH oxidase, electrons must be transferred 
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to 02 without its ligation to haem iron. It has been 
proposed that this occurs by electron donation to 0 2 at the 
haem edge [22] as has been proposed for reduction of 
ferric cytochrome c by O~ [45], The cytochromes P-450 
are also known to catalyse production of O~ through 
autoxidation of the oxygen-bound form, e.g. [46,47]. The 
cytochrome component of P-450 BM3 has little primary 
structure homology with the leucocyte haem enzyme, but 
there is much conservation of structure between the flavo- 
protein components of P-450 BM3 and the leukocyte 
oxidase [16]. Interestingly, the NADPH oxidase flavo- 
protein has also been reported to catalyse superoxide pro- 
duction independently of its cytochrome [25]. 
Diphenyliodonium (IDP) and its analogue diphenyl- 
eneiodonium (DPI) act as potent inhibitors of the NADPH 
oxidase system in various leukocyte cells [48,49] and in 
fibroblasts [50]. These iodonium compounds have been 
shown to react by abstraction of an electron from a nucle- 
ophile to form a radical, which then adds back to the 
nucleophile to form a covalent adduct [51]. The formation 
of DPI-and IDP-flavin adducts has been observed uring 
inactivation of the neutrophil NADPH oxidase and reac- 
tion with flavins is postulated as the common mechanism 
by which IDP and its analogues act as inhibitors of various 
flavoenzymes [38]. Most recently, the formation of pheny- 
lated FMN has been demonstrated during inhibition of rat 
microsomal P-450 reductase by IDP [39]. We demonstrate 
here that IDP also inhibits fatty acid hydroxylase activity 
of P-450 BM3, and NADPH oxidase and cytochrome c
reductase activities of P-450 BM3 and its reductase do- 
main. IDP also inhibits lucigenin chemiluminescence 
caused by the NADPH oxidase activity of P-450 BM3 and 
its reductase. The inhibition is catalysis-dependent, i dicat- 
ing that reduction of IDP is a prerequisite for its action. 
The initial stimulation of substrate-independent NADPH 
oxidation seen in the presence of IDP is due to utilisation 
of IDP as a reducing substrate during the process of 
formation of its inhibitory form -as recently demonstrated 
with a mammalian P-450 reductase [39]. For both P-450 
BM3 and the leukocyte NADPH oxidase, IDP inhibits 
superoxide production by inactivation of electron flow 
through the flavins. In the case of the leukocyte oxidase, 
this prevents electrons reaching the haem (the major site of 
0 2 activation). For P-450 BM3, the flavins themselves act 
as mediators of electron transfer to 0 2 . The capacity of 
flavoprotein electron transferases to generate superoxide 
anions has recently been reviewed [52]. 
The substrate-independent NADPH oxidation catalysed 
by P-450 BM3 and its reductase domain may provide 
explanations for unusual observations reported uring pre- 
vious studies of the enzyme. Firstly, Narhi and Fulco [7] 
observed a time-dependent i activation of P-450 BM3 in 
the presence of NADPH and suggested that this might be 
due to an NADPH-induced conformational change from a 
'high activity' to a 'low activity' form of the enzyme. Full 
activity was found to be restored by dialysis to remove the 
NADPH. Studies in our laboratories confirm the time-de- 
pendent inactivation effect of NADPH. However, our CD 
studies indicate that secondary structure of P-450 BM3 
and its reductase domain are not significantly altered by 
incubation with 0.2 mM NADPH. Our other findings 
indicate that pre-incubation of P-450 BM3 with NADPH 
would result in oxidation of the cofactor at a rate approx. 
103-fold lower than that seen in the presence of substrate. 
The generation of NADP ÷ (a competitive inhibitor) may 
partially explain the inhibitory effect of P-450 BM3 pre- 
incubation with excess NADPH. Secondly, Peterson and 
Boddupalli [53] reported that between five and six electron 
equivalents per mole of enzyme are required to fully 
reduce P-450 BM3 with NADPH under an atmosphere of
carbon monoxide, and that a sharp endpoint is not obtained 
in this titration. The necessity for excess NADPH may be 
due to its slow oxidation by the enzyme, using traces of 
oxygen remaining in solution as an electron acceptor. 
In this report, we demonstrate he ability of the reduc- 
tase domain of P-450 BM3 to generate 0 2independently 
of its cytochrome and demonstrate the applicability of 
chemiluminescence techniques to its study. The reductase 
domain is highly homologous with mammalian hepatic 
P-450 reductase, which is responsible for the reduction of 
P-450s involved in drug and xenobiotic bioconversions. 
These studies strongly suggest hat NADPH-cytochrome 
P-450 reductase nzymes may be a significant source of 
production of oxygen free radical species in vivo -particu- 
larly if there is imbalance between the relative availabili- 
ties of NADPH and P-450 substrates in the cell. Given the 
current interest in the roles of oxygen radical species in the 
development of such mammalian pathological states as 
inflammation, Parkinson's disease, atherosclerosis, cardio- 
vascular disease and cancer, e.g., [54-58], this finding 
should merit further investigation. 
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